-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$36.0093.55% Upside
Summit Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Summit Therapeutics Inc.?
Summit Therapeutics Inc. has been rated by research analysts at Summit Redstone Partners, Stifel Nicolaus, H.C. Wainwright in the past 90 days.